Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 601–700 of 702
Blood Pressure Control in Patients with Glomerulonephritis
Ishimitsu, T. (2011) · InTech eBooks · doi:10.5772/23612
“In addition, there is another study reported that an ACE inhibitor improved renal outcomes in Chinese patients with advanced stage of non-diabetic renal disease whose serum creatinine ranged 3.1 to 5.0mg/dL (30).”
BackgroundInfluentialHilgers, K. F. (2009) · Der Nephrologe · doi:10.1007/s11560-009-0302-z
Prevención de la enfermedad renal crónica II: medidas específicas
Abodovsky, M. A. (2009) · Medwave · doi:10.5867/medwave.2009.12.4305
Stiefelhagen, P. (2007) · Der Internist · doi:10.1007/s00108-006-1788-3
Díez, J. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)73256-4
Marín, R., Gorostidi, M., Navascués, R. A., & Melendreras, S. G. (2009) · Medicina Clínica · doi:10.1016/s0025-7753(09)70958-3
Cardiovascular Death in Uremia—More Complex Than We Thought
Ritz, E. (2008) · Hong Kong Journal of Nephrology · doi:10.1016/s1561-5413(08)60013-7
“The administration of angiotensin-converting enzyme inhibitors (ACEIs) in patients with early and advanced CKD is safe, particularly with respect to hyperkalemia [43], but unfortunately, in elderly hemodialysed patients, per protocol analysis of a French study found no significant benefit from fosinopril (relative ris…”
BackgroundBenazepril is renoprotective in patients with severe chronic kidney disease
Kamper, A. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0230
Chung, S., & Park, C. W. (2011) · The Korean Journal of Internal Medicine
Microalbuminuria and Kidney Disease: An Evidence-based Perspective
Kalaitzidis, R., Dalal, P., & Bakris, G. L. (2010) · Springer eBooks · doi:10.1007/978-88-470-1463-3_9
“MDRD [41] Captopril Trial [42] AIPRI [43] Bakris GL [44] REIN [45] IDNT [46] AASK [47] RENAAL [48] REIN-2 [49] ABCD [50]a Hou et al [ 51 ]”
BackgroundYuan#, F.-H. (2012) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp12.192
Impact of enalapril on renal function in patients with severe chronic kidney disease
Vernaglione, L. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl527
Drug Prescription in Chronic Kidney Disease
Kielstein, J. T. (2014) · Springer eBooks · doi:10.1007/978-3-642-54637-2_27
RAAS Intervention in Chronic Kidney Disease
Lucas, C. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Renin–angiotensin–aldosterone system blockade in hypertensive patients with chronic kidney disease
(2013) · Blood Pressure · doi:10.3109/08037051.2013.852376
“6 g/day) [10] use of benazepril was associated with a 43% reduc-”
Schocken, D. D., Weber, M. A., Oparil, S., Ortíz, E., Reisin, E., Rich, M. W., Frishman, W. H., Jaigobin, C. S., Kostis, J. B., Artinian, N. T., et al. (2011)
The Interdisciplinary Chronic Kidney Disease Clinic
Bauer, C. A., Yee, J., & Campbell, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00048-2
ACE Inhibitor for Advanced Renal Insufficiency
Krumholz, H. M., & Sm (2006) · Journal watch · doi:10.1056/jc200602230000005
Blockage of renin-angiotensin System in Chronic Kidney Disease: Where Are We Now?
Chang, Y., & Sung, J. (2009) · Acta Nephrologica
La prevenzione primaria e secondaria dell'ipertensione arteriosa: il punto di vista del nefrologo
Andrulli, S., Mancuso, S., Bigi, M. C., Granata, A. R. M., Logias, F., Floccari, F., & Lullo, L. D. (2012) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.1177/039493621202400109
ACE Inhibitor Is Beneficial in Advanced Renal Insufficiency
Brett, A. S. (2006) · Journal watch · doi:10.1056/jw200601170000001
Kennen Sie die sieben Todsünden? Unverzeihliche Verordnungsfehler bei eingeschränkter Nierenfunktion
Kielstein, J. T. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-2918-9
Cardiovascular Problems in Chronic Kidney Disease
Ritz, E., & Remppis, A. (2009) · doi:10.1093/med/9780199566990.003.1502
The patient with CHF and renal dysfunction
Gardner, R. S., McDonagh, T. A., & Walker, N. L. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199674152.003.0021
金子, 佳., 一衛, 成., & 文武, 下. (2007) · 日本腎臓学会誌 · doi:10.14842/jpnjnephrol1959.49.19
Chronic kidney disease : a complex network of leukocyte dysfunction and inflammation
Mansouri, L. (2016) · Figshare
Lepeytre, F., Cardinal, H., Fradette, L., Verhave, J. C., Dorais, M., LeLorier, J., Pichette, V., & Madore, F. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw144
“ACE inhibitors and angiotensin II receptor blockers have been shown to reduce the progression of CKD in diabetics [15, 16] and non-diabetic proteinuric CKD patients [17], a finding that extends to patients with stage 4 CKD [18].”
BackgroundRAAS Blockade as First-Line Antihypertensive Therapy among People with CKD
Georgianos, P. I., Balaskas, E. V., & Zebekakis, P. E. (2017) · InTech eBooks · doi:10.5772/66180 · Cited by 1
“Additional benefits of the ACE inhibitor therapy were an associated 52% reduction in the level of proteinuria along with a 23% slower rate of eGFR decline [14].”
Background이주현 (2013) · YUHSpace (Yonsei University Medical Library)
Clinical and Physiological Aspects of Salt Sensitive Hypertension
Wolley, M. J. (2017) · The University of Queensland · doi:10.14264/uql.2017.1041
Determinants of Hypertensive Renal Disease and Its Progression
Griffin, K. A., Polichnowski, A. J., & BIDANI, A. K. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_27
Arterielle Hypertonie und Niereninsuffizienz
Pruijm, M., Battegay, E., & Burnier, M. (2009) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2009.06872
Pharmacologic Treatment of Hypertension
Sica, D. A., & Gehr, T. W. B. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50037-1
Sodhi, R. K., Philipneri, M., & Schmitz, P. G. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0029
Renin-Angiotensin System Blockers and Acute Kidney Injury
Vecchio, L. D., & Locatelli, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00228-4
Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy
Ahmadmehrabi, S., Rincon-Choles, H., & Tang, W. H. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-21033-5_8 · Cited by 1
Lanthier, L., Masse, M., Plourde, M.-É., & Cauchon, M. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.11.008
Is there a certain creatinine cutoff that an ACE-I should be discontinued in chronic kidney disease?
Slipman, R. A. (2019) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000274
Molokhia, E. A., Davis, B., Tran, Q., Campbell, K. C., & Warren, P. (2019) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000180
[Effect of salt intake on residual renal function in rats receiving peritoneal dialysis].
Kang, H., Wang, Y., Zhong, X., Yin, W., Li, F., & Jiang, J. (2021) · PubMed · doi:10.12122/j.issn.1673-4254.2021.02.15 · Cited by 1
Self-citationHanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch23
Reimbursement Team (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.119
Fornoni, A., León, C., & Raij, L. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-72659-5_18
A new era in cardio-renal risk management: overview of landmark papers published in NDT in 2021
de Borst, M. H. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac017
“The observational nature of this and similar studies published previously precludes firm conclusions on causality, but given trial data that ACEi treatment reduces the risk of mortality or kidney failure also in advanced CKD,(4) there seems a strong basis to further explore interventions that could facilitate its cont…”
ResultInfluentialCurrent awareness: Pharmacoepidemiology and drug safety
(2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1179
Huang, X., Lin, Q., Shen, M., Yang, M., Lin, J., Chen, Y., Li, J., Lu, F., Wang, L., Yang, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1416117/v1
García‐Prieto, A., Verdalles, Ú., & Goicoechea, M. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.023
Gómez-Alamillo, C., Fraile, M. G., Fernández‐Fresnedo, G., & Rodríguez, M. A. (2011) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(11)70125-1
Geriatric pharmacotherapy updates
Guay, D. R. P. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.06.007
Sharma, K. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50033-0
Chapter 8: Future directions and controversies
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.58
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch11
Hanna, E. B. (2017) · Wiley eBooks · doi:10.1002/9781119233503.ch23
Thuraisingham, R. C., & Adu, D. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4470-3.50019-7 · Cited by 1
Management of Diabetic Nephropathy
Conway, B. R., Goddard, J. G., Jaap, A. J., & Patrick, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_38
Effect of Different Treatment Strategies on the Prognosis of Malignant Hypertension Patients
张, 嘉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124487
Tirmenštajn‐Janković, B., & Bastać, D. (2022) · Timocki medicinski glasnik · doi:10.5937/tmg2202084t
Berbari, A. E., Daouk, N. A., & Daouk, M. M. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_25
Specificities in hypertension treatment in patients with chronic kidney disease
Simić‐Ogrizović, S. (2023) · Galenika Medical Journal · doi:10.5937/galmed2306090s
Kommentar zu „RAS-Inhibitoren bei schwerer Niereninsuffizienz ohne prognostischen Effekt“
Hilgers, K. F., & Mann, J. F. E. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1996-5839
Hoyer, J. D., Russ, P., & Mann, J. F. E. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00674-2
Liao, Y.-C., Wu, M., Huang, Y., Chou, C., & Yen, H. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.11.002
Drugs Affecting Renin-Angiotensin System
Khan, M. O. F., & Murphy, K. (2024) · Medicinal chemistry for pharmacy students · doi:10.2174/9789815179729124030004
Bhandari, S., Mehta, S. P., Khwaja, A., Cleland, J. G. F., Ives, N. J., Brettell, E. A., Chadburn, M., Cockwell, P., & for the STOP-ACEi Trial Investigators (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ttmc6210 · Cited by 1
Zhang, X., Zhao, J., Fan, Y., Huang, H., Gao, D., Ji, L., & Zhang, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4808370
Self-citationNew Insights into Kidney Diseases
Katayama, K., & Dohi, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312536
Ураження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Advancements in the Research of Non-Immunosuppressive Therapies for Chronic Kidney Disease
王, 欣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151288
Li, M., Wei, Y., & Shi, M. J. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob00238a
Zhao, M., Ma, F., & Chen, J. (2025) · Mendeleev Communications · doi:10.71267/mencom.7707
Reconsidering discontinuation of RAS inhibitors after hyperkalemia
Azegami, T., & Hayashi, K. (2025) · Hypertension Research · doi:10.1038/s41440-025-02256-2
Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies
Singh, H., Puckett, C., & Lucas, Y. Q. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165883
“These RASis are recommended at the highest tolerated or permissible doses due to their demonstrated ability to reduce blood pressure and proteinuria, slow the progression of eGFR decline and decrease the risks of kidney failure, CV complications and all-cause mortality [35–38].”
Prabhakaran, M., & Parthasarathy, K. (2025) · Synlett · doi:10.1055/a-2744-1923
White, C. M., Powell, J. N., & Driver, T. G. (2025) · Progress in heterocyclic chemistry · doi:10.1016/b978-0-443-44354-1.00006-1
Conway, B. R., Goddard, J. G., Jaap, A. J., & Patrick, A. W. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5547-8_32
Sullivan, M. K., Carrero, J.-J., Jani, B., Anderson, C., McConnachie, A., Hanlon, P., Nitsch, D., McAllister, D., Mair, F. S., Mark, P. B., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21456121
Lange, L. B., & Bistrup, C. (2025) · Trials · doi:10.1186/s13063-025-09244-4
“…to the broader population of persons with chronic kidney disease but without type 2 diabetes, for whom angiotensin-converting enzyme inhibitors (ACEi) previously was the only pharmacologic treatment that with significantly evidence, had shown to prevent kidney failure [22, 23] and lowering U-ACR.”
Dong, Y., Chang, C., Wu, L., & Toh, S. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70323
Cai, J., Li, Y., & Han, Y. (2026) · Cardiac Research · doi:10.1097/re9.0000000000000008
Stopping renin–angiotensin–aldosterone system inhibitors in kidney disease
Lecea, E. M. G., Frazier, K., & Ku, E. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001173
Jefferson, A., Narvekar, P., Roehm, B. A., Toto, R. D., Roth, L. R., & Grodin, J. L. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00754-z
Le donneur de rein décédé, principes physiopathologiques et innovations thérapeutiques
Kerforne, T. (2018) · theses.fr (ABES) · doi:10.70675/f25441cfz0e1bz40f5zbae0z0ea1d0037f9f
“Cette néphroprotection repose sur le contrôle de la pression artérielle avec comme molécules de choix les inhibiteurs de l’enzyme de conversion de l’angiotensine ou les antagonistes des récepteurs à l’angiotensine 2 (Hou et al., 2006) associés éventuellement à des diurétiques.”
Villain, C. (2019) · theses.fr (ABES) · doi:10.70675/54f7af36z8650z49b2zb6a9z4b47be97b748 · Cited by 1
Cardiovascular benefit of blood-pressure lowering in chronic kidney disease
Sun, Y., & Guo, X. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00553-2
Ferrin, Z. R., & Lindsay, V. N. G. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c01913
Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy
Kondyli, M., Siwy, J., Campos, M. A. J., Amann, K., Beige, J., Keller, F., Mischak, H., Frantzi, M., Wendt, R., Rossing, P. R., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113396
Zhang, X., Zhang, X., Zhao, J., Fan, Y., Song, S., Huang, H., Gao, D., Ji, L., & Zhang, Z. (2026) · Lupus Science & Medicine · doi:10.1136/lupus-2026-002025
“These findings challenge the direct extrapolation of guidelines from diabetic nephropathy to the induction therapy for LN. Future trials are warranted to assess long-term protection of RASi against the progression of chronic kidney disease.”
Self-citationAntihypertensive Treatment in Chronic Kidney Disease: Current Algorithms
Theodorakopoulou, M. P., & Sarafidis, P. A. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_12
Gimenez-Stamminger, N., Mateus, C., Mason, T., & Harding, A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354854
Lu, F., Ahmed, A. A., Zhang, S., Raman, V. K., Patel, S. S., Vargas, J. D., Fonarow, G. C., Heidenreich, P. A., Cleland, J. G. F., Anker, S. D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag237
Zhao, S., Wang, X., Li, S., & Zhao, J. (2026) · Chemical Communications · doi:10.1039/d6cc03457h
Arundel, C., Raman, V. K., Zhang, S., Sheriff, H. M., Logan, J. J., Vargas, J. D., Moore, H. J., Karasik, P., Lam, P. H., Patel, S. S., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.08.007
Daniel, F. L., Ezhilgnanadevi, E., & Srinivasan, K. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c01060
Synthesis of Benzo[ b ]azepines via Intramolecular Cyclization of 2-Alkenyl- N -propargylanilines
Sharma, A., Sharma, P., Shukla, R., Changotra, A., & Gurubrahamam, R. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c03870
Inker, L. A., Heerspink, H. J., Tighiouart, H., Miao, S., Chaudhari, J., Vecchio, L. D., Floege, J., Hannedouche, T., Imai, E., Jafar, T. H., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.08.030
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.